Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

DDR1/2 enhance KIT activation and imatinib resistance of primary and secondary KIT mutants in gastrointestinal stromal tumors

Liu, Anbu ; Zhang, Shaoting ; Wang, Ming ; Zhang, Liangying ; Xu, Shidong ; Nasimian, Ahmad LU ; Li, Shujing ; Zhao, Sien ; Cao, Xu and Tian, Jinhai , et al. (2024) In Molecular Carcinogenesis 63(1). p.75-93
Abstract

Gastrointestinal stromal tumors (GISTs) are predominantly initiated by KIT mutations. In this study, we observed that discoidin domain receptors 1 and 2 (DDR1 and DDR2) exhibited high expression in GISTs, were associated with KIT, and enhanced the activation of both wild-type KIT and primary KIT mutants. Inhibition of DDR1/2 led to a reduction in the activation of KIT and its downstream signaling molecules, ultimately impairing GIST cell survival and proliferation in vitro. Consequently, treatment of mice carrying germline KIT/V558A mutation with DDR1/2 inhibitor significantly impeded tumor growth, and the combined use of DDR1/2 inhibitor and imatinib, the first-line targeted therapeutic agent for GISTs, markedly enhanced tumor growth... (More)

Gastrointestinal stromal tumors (GISTs) are predominantly initiated by KIT mutations. In this study, we observed that discoidin domain receptors 1 and 2 (DDR1 and DDR2) exhibited high expression in GISTs, were associated with KIT, and enhanced the activation of both wild-type KIT and primary KIT mutants. Inhibition of DDR1/2 led to a reduction in the activation of KIT and its downstream signaling molecules, ultimately impairing GIST cell survival and proliferation in vitro. Consequently, treatment of mice carrying germline KIT/V558A mutation with DDR1/2 inhibitor significantly impeded tumor growth, and the combined use of DDR1/2 inhibitor and imatinib, the first-line targeted therapeutic agent for GISTs, markedly enhanced tumor growth suppression. In addition, DDR1/2 inhibition resulted in decreased KIT expression, while KIT inhibition led to upregulation of DDR1/2 expression in GISTs. The presence of DDR1/2 also decreased the sensitivity of wild-type KIT or primary KIT mutants to imatinib, indicating a possible role for DDR1/2 in promoting GIST survival during KIT-targeted therapy. The development of drug-resistant secondary KIT mutations is a primary factor contributing to GIST recurrence following targeted therapy. Similar to primary KIT mutants, DDR1/2 can associate with and enhance the activation of secondary KIT mutants, further diminishing their sensitivity to imatinib. In summary, our data demonstrate that DDR1/2 contribute to KIT activation in GISTs and strengthen resistance to imatinib for both primary and secondary KIT mutants, providing a rationale for further exploration of DDR1/2 targeting in GIST treatment.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
DDR, GIST, imatinib, KIT, mutation
in
Molecular Carcinogenesis
volume
63
issue
1
pages
19 pages
publisher
John Wiley & Sons Inc.
external identifiers
  • pmid:37737519
  • scopus:85171805457
ISSN
0899-1987
DOI
10.1002/mc.23637
language
English
LU publication?
yes
id
5d212ac4-9236-4897-96f3-876753670906
date added to LUP
2023-12-22 09:40:06
date last changed
2024-04-20 19:00:53
@article{5d212ac4-9236-4897-96f3-876753670906,
  abstract     = {{<p>Gastrointestinal stromal tumors (GISTs) are predominantly initiated by KIT mutations. In this study, we observed that discoidin domain receptors 1 and 2 (DDR1 and DDR2) exhibited high expression in GISTs, were associated with KIT, and enhanced the activation of both wild-type KIT and primary KIT mutants. Inhibition of DDR1/2 led to a reduction in the activation of KIT and its downstream signaling molecules, ultimately impairing GIST cell survival and proliferation in vitro. Consequently, treatment of mice carrying germline KIT/V558A mutation with DDR1/2 inhibitor significantly impeded tumor growth, and the combined use of DDR1/2 inhibitor and imatinib, the first-line targeted therapeutic agent for GISTs, markedly enhanced tumor growth suppression. In addition, DDR1/2 inhibition resulted in decreased KIT expression, while KIT inhibition led to upregulation of DDR1/2 expression in GISTs. The presence of DDR1/2 also decreased the sensitivity of wild-type KIT or primary KIT mutants to imatinib, indicating a possible role for DDR1/2 in promoting GIST survival during KIT-targeted therapy. The development of drug-resistant secondary KIT mutations is a primary factor contributing to GIST recurrence following targeted therapy. Similar to primary KIT mutants, DDR1/2 can associate with and enhance the activation of secondary KIT mutants, further diminishing their sensitivity to imatinib. In summary, our data demonstrate that DDR1/2 contribute to KIT activation in GISTs and strengthen resistance to imatinib for both primary and secondary KIT mutants, providing a rationale for further exploration of DDR1/2 targeting in GIST treatment.</p>}},
  author       = {{Liu, Anbu and Zhang, Shaoting and Wang, Ming and Zhang, Liangying and Xu, Shidong and Nasimian, Ahmad and Li, Shujing and Zhao, Sien and Cao, Xu and Tian, Jinhai and Yu, Yuanyuan and Fan, Zhaoyang and Xiao, Kun and Zhao, Hui and Kazi, Julhash U. and Ma, Lijun and Sun, Jianmin}},
  issn         = {{0899-1987}},
  keywords     = {{DDR; GIST; imatinib; KIT; mutation}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{75--93}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{Molecular Carcinogenesis}},
  title        = {{DDR1/2 enhance KIT activation and imatinib resistance of primary and secondary KIT mutants in gastrointestinal stromal tumors}},
  url          = {{http://dx.doi.org/10.1002/mc.23637}},
  doi          = {{10.1002/mc.23637}},
  volume       = {{63}},
  year         = {{2024}},
}